Atorvastatin does not alter interferon Beta-induced changes of serum matrix metalloproteinase 9 and tissue inhibitor of metalloproteinase 1 in patients with multiple sclerosis.
Sellner
Johann
J
Greeve
Isabell
I
Leib
Stephen L
SL
Mattle
Heinrich P
HP
D000276:Adjuvants, Immunologic / Q000008:administration & dosage; D000328:Adult; D000069059:Atorvastatin; D015415:Biomarkers / Q000032:analysis / Q000097:blood; D002490:Central Nervous System / Q000187:drug effects / Q000201:enzymology / Q000503:physiopathology; D004347:Drug Interactions / Q000276:immunology; D004359:Drug Therapy, Combination; D006538:Heptanoic Acids / Q000008:administration & dosage* / Q000009:adverse effects; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000008:administration & dosage / Q000009:adverse effects; D007155:Immunologic Factors / Q000008:administration & dosage / Q000009:adverse effects; D000068576:Interferon beta-1b; D016899:Interferon-beta / Q000008:administration & dosage*; D020780:Matrix Metalloproteinase 9 / Q000097:blood / Q000187:drug effects*; D020529:Multiple Sclerosis, Relapsing-Remitting / Q000097:blood / Q000188:drug therapy* / Q000201:enzymology*; D011758:Pyrroles / Q000008:administration & dosage* / Q000009:adverse effects; D019715:Tissue Inhibitor of Metalloproteinase-1 / Q000097:blood / Q000187:drug effects*; D016896:Treatment Outcome
D000276:Adjuvants, Immunologic; D015415:Biomarkers; D006538:Heptanoic Acids; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D007155:Immunologic Factors; D011758:Pyrroles; D019715:Tissue Inhibitor of Metalloproteinase-1; D000068576:Interferon beta-1b; D016899:Interferon-beta; D000069059:Atorvastatin; D020780:Matrix Metalloproteinase 9